tbuckley/cabot-search huggingface dataset:
RARE-15. POSTOPERATIVE MANAGEMENTS FOR ADULT PILOCYTIC ASTROCYTOMAS: EFFICACY OF UPFRONT RADIATION THERAPY AND RADIOSURGERY
Authors: Young Hoon Kim, Jeong Hoon Kim
Journal: Neuro-Oncology (2016)

Adult pilocytic astrocytomas (PAs) are rare and have more aggressive prognosis than pediatric patients. Postoperative management protocols for PAs have not been well documented whether the tumor was removed totally or not. This study was designed to evaluate the surgical outcome of adult PAs and to assess the efficacy of the upfront radiation therapy (RTx) and radiosurgery for residual tumors. A total of 63 consecutive adult patients with newly diagnosed PAs were retrospectively reviewed. Thirty-Two patients (50.8%) were male, and the median patient age was 28 years (range, 18 – 79 years). There were 21 supratentorial hemisphere tumors (33.3%), 11 supratentorial axial tumors (17.5%), and 31 infratentorial tumors (49.2%). Fifty-four patients (85.7%) underwent surgical resection and 9 patients (14.3%) did only biopsy. Forty-one patients (65.1%) underwent gross total removal (GTR), 13 patients (20.6%) subtotal removal (STR), and 9 patients (14.3%) only biopsy. The recurrence rates were 9.8% (4/41), 23.1% (3/13), and 55.6% (5/9) in the GTR, STR, and biopsy group, respectively, and the overall recurrence rate was 19.0% (12/63). Of the 22 patients who did not underwent GTR, 7 patients received RTx, 4 patients reoperation, 3 patients radiosurgery, and 8 patients observation. The final recurrence rates were 57.1% (4/7), 33.3% (1/3), and 25% (2/8) in the RTx, radiosurgery, and observation groups, respectively. The adult PAs showed more aggressive clinical course. The efficacy of the upfront RTx or radiosurgery was questionable.
Metformin and longevity (METAL): A window of opportunity study investigating the biological effects of metformin in localised prostate cancer
Authors: D. Crawley, A. Chandra, M. Loda, C. Gillett, P. Cathcart, B. Challacombe, G. Cook, D. Cahill, F. Cahill, A. Santa Olalla, G. George, S. Rudman, M. van Hemelrijck
Journal: Annals of Oncology (2016)
Outcomes of peri-operative chemotherapy (PO-CT) for locally advanced penile squamous cell carcinoma (LA-PSCC): results from a multicenter analysis
Authors: A. Necchi, G.R. Pond, D. Raggi, S. Ottenhof, S. Horenblas, V. Khoo, O. Hakenberg, A. Heidenreich, B.J. Eigl, L. Nappi, K. Matsumoto, U. Vaishampayan, M. Woods, P. Giannatempo, D. Geynisman, M. Preto, E. Xylinas, M.I. Milowsky, G. Di Lorenzo, G. Sonpavde
Journal: Annals of Oncology (2016)
SURG-24. SURGICAL RESECTION OF FOURTH VENTRICULAR EPENDYMOMAS – CASE SERIES AND TECHNICAL NUANCES
Authors: Ethan Winkler, Harjus Birk, Michael Safaee, John Yue, John Burke, Jennifer Viner, Melike Pekmezci, Arie Perry, Manish Aghi, Mitchel S. Berger, Michael McDermott
Journal: Neuro-Oncology (2016)

Ependymomas are rare neuroepithelial tumors which may arise anywhere along the ventricular system. Tumors arising in the 4th ventricle present unique challenges. Complete tumor resection favors prolonged survival, but may result in inadvertent injury of surrounding neural structures –such as cranial nerve (CN) nuclei. Here, our institutional experience with surgical resection of 4thventricular ependymomas is described. A single institution, retrospective analysis of consecutive case series of adult surgically resected 4thventricular ependymomas with the bilateral telovelar approach. Extent of resection, outcomes and postoperative complications are statistically analyzed. From January 2000 to April 2016, twenty-two 4thventricular ependymomas underwent surgical resection. Gross total resection was achieved in 18 of 22 cases (82%). There were six postoperative CN palsies – 3 lower CN palsies (IX, X, or XI), 1 CN VII palsy, 1 CN IV palsy, and 1 CN VI palsy. No deaths or cerebellar mutism occurred. Two of 6 CN deficits resolved and the rate of permanent neurologic deficit was 18%. A CN deficit was not statistically associated with prolonged hospital stay or functional outcome. With exception of one patient, all patients functionally improved or remained unchanged following surgery. Postoperative complications included 1 wound infection (4.5%) and 4 pseudomeningoceles (18%). The rate of shunt-dependent hydrocephalus was 18%. Tumor adherence to the 4thventricular floor is not an absolute contraindication for complete resection. Intraoperative neuro-monitoring is essential, and the development of sustained, but not transient CN activity, and/or hemodynamically significant bradycardia should limit the extent of resection.
Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative 18F-FDG PET/CT in Patients With Renal Cell Carcinoma
Authors: Reiko Nakajima, Yuka Matsuo, Tsunenori Kondo, Koichiro Abe, Shuji Sakai
Journal: Clinical Nuclear Medicine (2017)

We evaluated the prognostic value of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) measured using pretreatment F-FDG PET/CT in patients with renal cell carcinoma (RCC).A total of 139 patients with RCC who had undergone FDG PET/CT before tumor resection were retrospectively reviewed. We determined the SUVmax, MTV, and TLG and compared the results obtained with those required for a progression-free survival (PFS), which was defined as disease progression. Receiver operating characteristic curve analysis was used to compare prediction accuracies. Univariate and multivariate analyses of conventional clinicopathologic variables (age, sex, pathological tumor node metastasis [pTNM] stage, histological type, Fuhrman grade, and presence/absence of microscopic lymphatic and venous invasions) were used to compare the reliability of the metabolic parameters (SUVmax, MTV, and TLG).Of the 139 patients, 24 patients (17%) experienced disease progression during the follow-up period. The age, pTNM stage, Fuhrman grade, presence/absence of microscopic lymphatic and venous invasions, SUVmax, MTV, and TLG were found to be significant prognostic factors for PFS (P < 0.05) on univariate analyses. Multivariate analyses revealed that MTV, TLG, and high pTNM stage (P = 0.02 [hazard ratio, 9.5; 95% confidence interval, 1.50-187.0], P = 0.02 [hazard ratio, 9.0; 95% confidence interval, 1.40-178.5], P = 0.004 [hazard ratio, 5.9; 95% confidence interval, 1.66-20.4], respectively) were the significant predictors after adjustment for other variables of PFS.The pretreatment value of MTV, TLG, and high pTNM stage are the significant prognostic factors in patients with RCC.
RTHP-24. PSEUDOPROGRESSION AFTER PROTON VS. PHOTON THERAPY IN PATIENTS WITH OLIGODENDROGLIOMA
Authors: Julianna K. Bronk, Nandita Guha-Thakurta, Anita Mahajan, David R. Grosshans, Susan L. McGovern
Journal: Neuro-Oncology (2016)

Proton therapy is increasingly used for treatment of primary brain tumors. Recent concern has emerged regarding potentially higher rates of pseudoprogression, the development of new enhancement within the radiation field, after proton therapy compared to photon therapy. Pseudoprogression can be difficult to distinguish from true progression and is poorly described for patients with oligodendroglioma. We retrospectively reviewed 68 patients with grade 2 or 3 oligodendroglioma treated with proton (n = 27) or photon (n = 41) therapy. All patients were treated between 2004 and 2015 and had a minimum of 6 months of radiographic follow up. Median radiographic follow-up after radiation was 35 months in the photon group and 22 months in the proton group. Pseudoprogression developed in 5/41 photon-treated patients (12%) and 5/27 proton-treated patients (19%) (p = 0.5). Of 41 patients treated with more than 54 Gy, 7 developed pseudoprogression (17%) vs. 3 of 27 patients treated with 54 Gy or less (11%; p = 0.7). Of 23 patients with grade 2 oligodendroglioma, 3 developed pseudoprogression (13%) vs. 7 of 45 (16%) patients with grade 3 oligodendroglioma (p = 1.0). 1p19q status was available for 56 patients; 6/44 (14%) of patients with 1p19q codeletion developed pseudoprogression vs. 1/12 (8%) of patients without 1p19q codeletion (p = 1.0). These findings suggest that there is no difference in rates of pseudoprogression after proton or photon therapy for oligodendroglioma. Early contrast enhancing imaging changes post-radiation therapy must be evaluated appropriately, regardless of the type of radiation delivered.
Late Increase of Peripheral CD34+ Cells Number during Acute Liver Failure Recovery.
Authors: Bernard Drénou, Anne Corlu, Yoann Desille, Christèle Sicot, Olivier Fardel, Laurence Amiot, Richard Lorho, Christophe Camus, Anne Guillygomarc’h, Karim Boudjema, Dominique Guyader
Journal: Blood (2005)
Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas.
Authors: Y. J. Park, S. Lee
Journal: Journal of Clinical Oncology (2011)

189 Background: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas has a favorable prognosis, but seems to be associated with a high incidence of extrapancreatic tumors. The purpose of this study was to evaluate the incidence and clinicopathologic features of extrapancreatic tumors associated with IPMN compared with pancreas cancer. Methods: Thirty-seven patients with IPMN of the pancreas and eighty-four patients with pancreas cancer, confirmed by surgical resection and typical findings of endoscopic ultrasonography and CT imaging between October 1, 1998, and August 31, 2009, were included. All pancreas cancers were diagnosed with surgical resection and biopsy. These patients were examined for the development of extrapancreatic tumors. Results: Of 37 patients with IPMN, 14 (38%) had 18 extrapancreatic tumors, and 10 (27%) had 13 extrapancreatic malignancies. Five, six, and two extrapancreatic malignancies had been diagnosed before, during, and after the diagnosis of IPMN. Gastric adenocarcinoma (3 patients, 23%) and colorectal carcinoma (3 patients, 23%) were the most common neoplasms. Other extrapancreatic tumors included lung cancer (n=2), prostatic cancer (n=1), renal cell carcinoma (n=1), cholangiocellular carcinoma (n=1), urinary bladder cancer (n=1), and gallbladder cancer (n=1), respectively. As benign tumor, there were two gallbladder adenoma, one gastric adenoma, one colonic adenoma and one benign ovarian cystic neoplasm, respectively. On the other side, of 84 patients with pancreas cancer, 9 (10%) had 9 extrapancreatic tumors and 2 (2%) had extrapancreatic malignancies which were stomach cancer (n=1, 1%) and breast cancer (n=1, 1%) respectively. As benign tumor, there were colon adenoma (n=3), hepatic hemangioma (n=2), gastric adenoma (n=1), and uterine myoma (n=1). Conclusions: IPMN is associated with high incidence of extrapancreatic tumors, particularly gastric and colorectal neoplasm but pancreas cancer did not show associations with extrapancreatic tumor. Upper gastrointestinal endoscopy and colonoscopy should be done, and systemic surveillance for the possible occurrence of other tumors may allow early detection of extrapancreatic tumor in patients with IPMN. No significant financial relationships to disclose.
Second Stem Cell Transplantation for Relapse of Childhood Hematologic Malignancies Following Initial Transplantation.
Authors: Nao Yoshida, Nobuhiro Watanabe, Kimikazu Matsumoto, Hirotoshi Sakaguchi, Asahito Hama, Yoshiyuki Takahashi, Naoko Maeda, Keizo Horibe, Seiji Kojima, Koji Kato
Journal: Blood (2010)
Frequency and intensity of symptoms and disease awareness in a large mono-institutional series of Malignant Pleural Mesothelioma (MPM) patients followed within a simultaneous care program
Authors: G. Gallizzi, F. Grosso, A. Kasa, B. Oneglia, P. Ballarino, A. Roveta, L. Giaretto, A. Muzio, G. Numico, D. Degiovanni
Journal: Annals of Oncology (2016)
Ultrasound‐Enhanced siRNA Delivery Using Magnetic Nanoparticle‐Loaded Chitosan‐Deoxycholic Acid Nanodroplets
Authors: Jeong Yu Lee, Calum Crake, Boon Teo, Dario Carugo, Marie de Saint Victor, Anjali Seth, Eleanor Stride
Journal: Advanced Healthcare Materials (2017)

Small interfering RNA (siRNA) has significant therapeutic potential but its clinical translation has been severely inhibited by a lack of effective delivery strategies. Previous work has demonstrated that perfluorocarbon nanodroplets loaded with magnetic nanoparticles can facilitate the intracellular delivery of a conventional chemotherapeutic drug. The aim of this study is to determine whether a similar agent can provide a means of delivering siRNA, enabling efficient transfection without degradation of the molecule. Chitosan‐deoxycholic acid nanoparticles containing perfluoropentane and iron oxide ( d 0 = 7.5 ± 0.35 nm) with a mean hydrodynamic diameter of 257.6 ± 10.9 nm are produced. siRNA (AllStars Hs cell death siRNA) is electrostatically bound to the particle surface and delivery to lung cancer cells and breast cancer cells is investigated with and without ultrasound exposure (500 kHz, 1 MPa peak‐to‐peak focal pressure, 40 cycles per burst, 1 kHz pulse repetition frequency, 10 s duration). The results show that siRNA functionality is not impaired by the treatment protocol and that the nanodroplets are able to successfully promote siRNA uptake, leading to significant apoptosis (52.4%) 72 h after ultrasound treatment.
P08.04 Antitumor effects of medroxyprogesterone on glial tumor growth in vitro and in vivo and an unexpected contribution of PI3Kinase on anti-invasive effects of steroids
Authors: M. A. Altinoz, F. H. Bolukbasi, J. Nalbantoglu, R. F. Del Maestro, I. Elmaci
Journal: Neuro-Oncology (2016)
Inhibitor Development in Previously Untreated Patients with Severe Hemophilia a Treated with Nuwiq®, a New Generation Recombinant FVIII of Human Origin
Authors: Raina Liesner, Marina Abashidze, Olga Aleinikova, Carmen Altisent, Mark J. Belletrutti, Annie Borel-Derlon, Manuel Carcao, Hervé Chambost, Anthony Chan, Leonid Dubey, Jonathan M. Ducore, Fouzia Nambiathayil Abubacker, Michael Gattens, Yves Gruel, Natalya Kavardakova, Mohamed Khorassani, Anna Klukowska, Christoph Königs, Thierry Lambert, Sunil Lohade, Marianne Sigaud, Valentin Turea, John K. Wu, Vladimir Vdovin
Journal: Blood (2016)
TMIC-09. EXPRESSION ANALYSIS OF IDH1 WILD-TYPE AND MUTANT GLIOMA STEM CELLS UNDER HYPOXIA IDENTIFIES NOVEL SURVIVAL-ASSOCIATED GENES IN GLIOBLASTOMA PATIENTS
Authors: Philip Dao Trong, Rolf Warta, Christoph Geisenberger, Heimo Mairbäurl, Stefan Pusch, Andreas Unterberg, Christel Herold-Mende
Journal: Neuro-Oncology (2016)

The hypoxic microenvironment seems to drive the glioma stem cell (GSC) phenotype and to promote resistance to radiation and differentiating agents. The IDH1 status has shown to play a crucial role in the prognosis and treatment of glioma patients. Most studies analyzing the behavior of IDH mutated (mut) and wildtype (wt) glioma cells or tumor tissue in different oxygen tensions have synthetically introduced the IDH1 mutation into common cell lines (e.g. U87MG, U251, A172) leading to inconsistent results. In our experiments we were able to isolate GSC from IDH1mut and –wt tumor tissue. Taking into account the natural genetic background, we performed expression analysis with IDH1mut and -wt GSC lines which were grown 72h under normoxic (20%) and hypoxic (1.5%) culture conditions. Possible survival associations of candidate genes were tested using the expression data from the GBM dataset of ‘The Cancer Genome Atlas’ (TCGA). The differential mRNA expression analyses revealed that strongest expression changes were seen in IDH1wt GSCs (34 genes vs. 0 genes). Further analyses of these 34 genes isolated three differentially overexpressed candidate genes in hypoxia (P4HA1, PPP1R15A and INSIG1) which showed a significant survival disadvantage in GBM IDHwt patients of the TCGA study population. Taken together this study suggests, that IDH1mut GSCs do not seem to react to hypoxia on the transcriptional level. In contrast, IDH1wt GSCs regulate 34 genes, of which three show a significant survival correlation in GBM IDHwt patients.
ATIM-15. A PHASE I TRIAL OF HYPOFRACTIONATED STEREOTACTIC IRRADIATION (HFSRT) WITH PEMBROLIZUMAB AND BEVACIZUMAB IN patients with recurrent high grade gliomas
Authors: Solmaz Sahebjam, Peter A. Johnstone, Peter Forsyth, John Arrington, Michael Jaglal, Nam D. Tran, Frank D. Vrionis, Arnold B. Etame, Melissa Wicklund, Anise L. Elie, Tyra Gatewood, Robert Macaulay, Prakash Chinnaiyan, Michael Yu
Journal: Neuro-Oncology (2016)

High grade gliomas carry a grim prognosis despite current therapies. Expression of PD-1 and PD-L1 is found in the microenvironment of most high grade gliomas. There is strong pre-clinical evidence for the combination of anti PD-1/PD-L1 blockade with radiotherapy and anti-angiogenic agents. This study evaluates the combination of pembrolizumab, an anti-PD-1 monoclonal antibody, with hypofractionated stereotactic irradiation (HFSRT) and bevacizumab. This phase I study (3+3 design) explores the safety, tolerability, recommended phase II dose (RP2D), and antitumor activity of pembrolizumab administered concurrently with HFSRT and bevacizumab (NCT02313272). Adult patients with recurrent glioblastoma (GBM) or anaplastic astrocytoma (maximum diameter of target lesion ≤ 3.5 cm) are eligible. Eligible patients receive HFSRT to the recurrent tumor (30 Gy delivered in 5 fractions) combined with bevacizumab (10 mg/kg, intravenously Q2W) and pembrolizumab (100 mg or 200 mg intravenously based on dose level, Q3W). Two dose levels of pembrolizumab (100 mg and 200 mg Q3W) are explored. After determination of RP2D, an additional 20 patients will be enrolled in an expansion cohort. Response is assessed every 6W per RANO criteria. Effect of treatment on quality of life measures are evaluated. As of June 2016, dose escalation cohort has been completed and accrual to dose expansion cohort is ongoing. Combination of HFSRT (30 Gy in 5 fractions) with pembrolizumab (200 mg every 3 weeks) and bevacizumab (10 mg/kg every 2 weeks) is well tolerated. No dose limiting toxicity or treatment-related neurologic adverse event has been observed. Six out of nine patients have achieved objective response (complete response + partial response). Preliminary data demonstrate an acceptable toxicity profile and encouraging anti-tumor activity. Updated safety and efficacy data will be presented.
JAK2 Inhibition with TG101348 Inhibits Monosomy 7 Myelodysplastic Syndromes (MDS) Bone Marrow Cells In Vitro: a Potential Targeted Therapy for Monosomy 7 MDS
Authors: Matthew J. Olnes, Andrea Poon, Zachary Tucker, Neal S. Young, Elaine M Sloand
Journal: Blood (2010)
Foxo1 Expressed in Osteoblasts Promotes the Leukemogenic Properties of β-Catenin By Activating Notch Signaling
Authors: Aruna Kode, Ioanna Mosialou, Sanil J Manavalan, Julie Teruya Feldstein, Govind Bhagat, Ellin Berman, Stavroula Kousteni
Journal: Blood (2014)
Minimal incision-assisted full-thickness sampling with over-the-scope clip targeting intestinal neuronal malformation
Authors: Noriko Nishiyama, Hirohito Mori, Hideki Kobara, Shintaro Fujihara, Maki Ayaki, Yumi Miyai, Tsutomu Masaki
Journal: Endoscopy (2017)

Intestinal neuronal malformation (INM) is a rare and refractory pediatric disease [1]. Its definitive diagnosis is generally confirmed by an invasive full-thickness biopsy [2]. This biopsy is required because the nerve plexus is located in the deep submucosal and muscle layers, resulting in poor diagnostic ability with endoscopic suction biopsies [3]. In our experience, even specimens obtained by endoscopic submucosal dissection fail to provide an accurate histological evaluation owing to the burn effects. As a result, full-thickness specimens must be obtained to make a diagnosis of INM.
Educating religious leaders to promote uptake of male circumcision in Tanzania: a cluster randomised trial
Authors: Jennifer A Downs, Agrey H Mwakisole, Alphonce B Chandika, Shibide Lugoba, Rehema Kassim, Evarist Laizer, Kinanga A Magambo, Myung Hee Lee, Samuel E Kalluvya, David J Downs, Daniel W Fitzgerald
Journal: The Lancet (2017)

Male circumcision is being widely deployed as an HIV prevention strategy in countries with high HIV incidence, but its uptake in sub-Saharan Africa has been below targets. We did a study to establish whether educating religious leaders about male circumcision would increase uptake in their village.In this cluster randomised trial in northwest Tanzania, eligible villages were paired by proximity (<60 km) and the time that a free male circumcision outreach campaign from the Tanzanian Ministry of Health became available in their village. All villages received the standard male circumcision outreach activities provided by the Ministry of Health. Within the village pairs, villages were randomly assigned by coin toss to receive either additional education for Christian church leaders on scientific, religious, and cultural aspects of male circumcision (intervention group), or standard outreach only (control group). Church leaders or their congregations were not masked to random assignment. The educational intervention consisted of a 1-day seminar co-taught by a Tanzanian pastor and a Tanzanian clinician who worked with the Ministry of Health, and meetings with the study team every 2 weeks thereafter, for the duration of the circumcision campaign. The primary outcome was the proportion of male individuals in a village who were circumcised during the campaign, using an intention-to-treat analysis that included all men in the village. This trial is registered with ClinicalTrials.gov, number NCT 02167776.Between June 15, 2014, and Dec 10, 2015, we provided education for church leaders in eight intervention villages and compared the outcomes with those in eight control villages. In the intervention villages, 52·8% (30 889 of 58 536) of men were circumcised compared with 29·5% (25 484 of 86 492) of men in the eight control villages (odds ratio 3·2 [95% CI, 1·4-7·3]; p=0·006).Education of religious leaders had a substantial effect on uptake of male circumcision, and should be considered as part of male circumcision programmes in other sub-Saharan African countries. This study was conducted in one region in Tanzania; however, we believe that our intervention is generalisable. We equipped church leaders with knowledge and tools, and ultimately each leader established the most culturally-appropriate way to promote male circumcision. Therefore, we think that the process of working through religious leaders can serve as an innovative model to promote healthy behaviour, leading to HIV prevention and other clinically relevant outcomes, in a variety of settings.Bill & Melinda Gates Foundation, National Institutes of Health, and the Mulago Foundation.
Ablation of periostin inhibits post-infarction myocardial regeneration in neonatal mice mediated by the phosphatidylinositol 3 kinase/glycogen synthase kinase 3β/cyclin D1 signalling pathway
Authors: Zhenhuan Chen, Jiahe Xie, Huixin Hao, Hairuo Lin, Long Wang, Yingxue Zhang, Lin Chen, Shiping Cao, Xiaobo Huang, Wangjun Liao, Jianping Bin, Yulin Liao
Journal: Cardiovascular Research (2017)

To resolve the controversy as to whether periostin plays a role in myocardial regeneration after myocardial infarction (MI), we created a neonatal mouse model of MI to investigate the influence of periostin ablation on myocardial regeneration and clarify the underlying mechanisms.
Nordic CML Study Group Quality and Standardization Rounds for Quantitative RT-PCR of BCR-ABL To Facilitate Reporting on the International Scale.
Authors: Hans Boström, Tuija Lundan, Morten Tolstrup Andersen, Gisela Barbany, Thoas Fioretos, Irina Golovleva, Jon Jonasson, Vesa Juvonen, Mikael Lindlöf, Mats Irgen Olsen, Niels Pallisgaard, Eeva-Riitta Savolainen, Marie Schaffer, Aleksandra Silye, Henrik Hjorth-Hansen, Magnus K. Magnusson, Johann Lanng Nielsen, Kimmo Porkka, Bengt Simonsson, Veli Kairisto
Journal: Blood (2007)
Erythroid Activity, Transfusion Iron Overload, and Hepcidin Levels in Patients with Myelodysplastic Syndrome
Authors: Luca Malcovati, Matteo G Della Porta, Coby M Laarakkers, Anna Gallì, Riccardo Albertini, Margherita Maffioli, Ilaria Ambaglio, Erica Travaglino, Rosangela Invernizzi, Remigio Moratti, Dorine W. Swinkels, Mario Cazzola
Journal: Blood (2008)